No Data
Akero Therapeutics Is Maintained at Outperform by Evercore ISI Group
Akero Therapeutics Is Maintained at Outperform by Evercore ISI Group
Evercore ISI Group Maintains Outperform on Akero Therapeutics, Lowers Price Target to $38
Evercore ISI Group analyst Liisa Bayko maintains Akero Therapeutics (NASDAQ:AKRO) with a Outperform and lowers the price target from $50 to $38.
Express News | Akero Therapeutics Inc : Evercore ISI Cuts Target Price to $38 From $50
Akero Therapeutics Price Target Cut to $56.00/Share From $59.00 by Canaccord Genuity
Akero Therapeutics Price Target Cut to $56.00/Share From $59.00 by Canaccord Genuity
Akero Therapeutics Is Maintained at Buy by Canaccord Genuity
Akero Therapeutics Is Maintained at Buy by Canaccord Genuity
Insiders Could Have Profited By Holding Onto Akero Therapeutics Shares Despite 11% Drop
Akero Therapeutics, Inc.'s (NASDAQ:AKRO) value has fallen 11% in the last week, but insiders who sold US$4.7m worth of stock over the last year have had less success. Insiders might have been better